Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Thymic Tumors and Lymphomas: The Clinical Impact of Their Underlying Molecular Features

  • Chapter
  • First Online:
The Mediastinal Mass

Part of the book series: Current Clinical Pathology ((CCPATH))

  • 578 Accesses

Abstract

Although rare, mediastinal tumors often present a challenge for both the physicians and the pathologists. Here we focus on the molecular features underlying thymic tumors and lymphomas, which are the most common malignancies occurring in the anterior compartment of the mediastinum. We discuss both established and recently discovered molecular alterations that can overall serve as diagnostic, prognostic, and predictive factors or possibly as targets for therapeutic intervention.

Francesca Pentimalli and Daniela Barone are co-first authors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Shields TW. General thoracic surgery. 1st ed. Philadelphis, PA: Lea and Febiger; 1972.

    Google Scholar 

  2. Liu W, Deslauriers J. Mediastinal divisions and compartments. Thorac Surg Clin. 2011;21(2):183–90, viii.

    Article  PubMed  Google Scholar 

  3. Carter BW, Tomiyama N, Bhora FY, Rosado de Christenson ML, Nakajima J, Boiselle PM, et al. A modern definition of mediastinal compartments. J Thorac Oncol. 2014;9(9 Suppl 2):S97–101.

    Article  PubMed  Google Scholar 

  4. Carter BW, Benveniste MF, Madan R, Godoy MC, de Groot PM, Truong MT, et al. ITMIG classification of mediastinal compartments and multidisciplinary approach to mediastinal masses. Radiographics. 2017;37(2):413–36.

    Article  PubMed  Google Scholar 

  5. Duwe BV, Sterman DH, Musani AI. Tumors of the mediastinum. Chest. 2005;128(4):2893–909.

    Article  PubMed  Google Scholar 

  6. Carter BW, Okumura M, Detterbeck FC, Marom EM. Approaching the patient with an anterior mediastinal mass: a guide for radiologists. J Thorac Oncol. 2014;9(9 Suppl 2):S110–8.

    Article  PubMed  Google Scholar 

  7. Carter BW, Marom EM, Detterbeck FC. Approaching the patient with an anterior mediastinal mass: a guide for clinicians. J Thorac Oncol. 2014;9(9 Suppl 2):S102–9.

    Article  PubMed  Google Scholar 

  8. Azizad S, Sannananja B, Restrepo CS. Solid tumors of the mediastinum in adults. Semin Ultrasound CT MR. 2016;37(3):196–211.

    Article  PubMed  Google Scholar 

  9. den Bakker MA, Marx A, Mukai K, Strobel P. Mesenchymal tumours of the mediastinum—part I. Virchows Arch. 2015;467(5):487–500.

    Article  CAS  Google Scholar 

  10. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon, France: IARC Press; 2004.

    Google Scholar 

  11. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 2010;5(10 Suppl 4):S260–5.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Scorsetti M, Leo F, Trama A, D’Angelillo R, Serpico D, Macerelli M, et al. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016;99:332–50.

    Article  PubMed  Google Scholar 

  13. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon, France: IARC Press; 2015.

    Google Scholar 

  14. Marx A, Chan JK, Coindre JM, Detterbeck F, Girard N, Harris NL, et al. The 2015 World Health Organization classification of tumors of the thymus: continuity and changes. J Thorac Oncol. 2015;10(10):1383–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Leisibach P, Schneiter D, Soltermann A, Yamada Y, Weder W, Jungraithmayr W. Prognostic value of immunohistochemical markers in malignant thymic epithelial tumors. J Thorac Dis. 2016;8(9):2580–91.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Tseng YL. Thymic carcinoma: a rare cancer requiring special attention. Formos J Surg. 2011;44(4):136–40.

    Article  Google Scholar 

  17. Kubonishi I, Takehara N, Iwata J, Sonobe H, Ohtsuki Y, Abe T, et al. Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res. 1991;51(12):3327–8.

    CAS  PubMed  Google Scholar 

  18. Lamarca A, Moreno V, Feliu J. Thymoma and thymic carcinoma in the target therapies era. Cancer Treat Rev. 2013;39(5):413–20.

    Article  CAS  PubMed  Google Scholar 

  19. Strobel P, Hohenberger P, Marx A. Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol. 2010;5(10 Suppl 4):S286–90.

    Article  PubMed  Google Scholar 

  20. Inoue M, Starostik P, Zettl A, Strobel P, Schwarz S, Scaravilli F, et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res. 2003;63(13):3708–15.

    CAS  PubMed  Google Scholar 

  21. Penzel R, Hoegel J, Schmitz W, Blaeker H, Morresi-Hauf A, Aulmann S, et al. Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer. 2003;105(4):494–8.

    Article  CAS  PubMed  Google Scholar 

  22. Inoue M, Marx A, Zettl A, Strobel P, Muller-Hermelink HK, Starostik P. Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am J Pathol. 2002;161(4):1507–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Petrini I, Wang Y, Zucali PA, Lee HS, Pham T, Voeller D, et al. Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. Clin Cancer Res. 2013;19(8):1960–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Petrini I, Meltzer PS, Zucali PA, Luo J, Lee C, Santoro A, et al. Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death Dis. 2012;3:e351.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Pentimalli F. BCL2: a 30-year tale of life, death and much more to come. Cell Death Differ. 2018;25(1):7–9.

    Article  CAS  PubMed  Google Scholar 

  26. Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet. 2014;46(8):844–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Gene mutation may signal indolent thymus cancer. Cancer Discov. 2014;4(9):OF4.

    Google Scholar 

  28. Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol. 2011;29(36):4820–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Scarpino S, Di Napoli A, Stoppacciaro A, Antonelli M, Pilozzi E, Chiarle R, et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol. 2007;149(3):504–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ionescu DN, Sasatomi E, Cieply K, Nola M, Dacic S. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer. 2005;103(3):630–6.

    Article  CAS  PubMed  Google Scholar 

  31. Pan CC, Chen PC, Wang LS, Lee JY, Chiang H. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology. 2003;43(2):165–72.

    Article  PubMed  Google Scholar 

  32. Weissferdt A, Lin H, Woods D, Tang X, Fujimoto J, Wistuba II, et al. HER family receptor and ligand status in thymic carcinoma. Lung Cancer. 2012;77(3):515–21.

    Article  PubMed  Google Scholar 

  33. Rajan A, Girard N, Marx A. State of the art of genetic alterations in thymic epithelial tumors. J Thorac Oncol. 2014;9(9 Suppl 2):S131–6.

    Article  PubMed  Google Scholar 

  34. Tiseo M, Damato A, Longo L, Barbieri F, Bertolini F, Stefani A, et al. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs). Lung Cancer. 2017;104:24–30.

    Article  PubMed  Google Scholar 

  35. Merveilleux du Vignaux C, Maury JM, Girard N. Novel agents in the treatment of thymic malignancies. Curr Treat Options in Oncol. 2017;18(9):52.

    Article  Google Scholar 

  36. Zucali PA, Petrini I, Lorenzi E, Merino M, Cao L, Di Tommaso L, et al. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer. 2010;116(20):4686–95.

    Article  PubMed  Google Scholar 

  37. Girard N, Teruya-Feldstein J, Payabyab EC, Riely GJ, Rusch VW, Kris MG, et al. Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol. 2010;5(9):1439–46.

    Article  PubMed  Google Scholar 

  38. Mimae T, Tsuta K, Kondo T, Nitta H, Grogan TM, Okada M, et al. Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas. Ann Oncol. 2012;23(12):3129–37.

    Article  CAS  PubMed  Google Scholar 

  39. Omatsu M, Kunimura T, Mikogami T, Hamatani S, Shiokawa A, Masunaga A, et al. Immunohistochemical analysis of thymic carcinoma focusing on the possibility of molecular targeted and hormonal therapies. Gen Thorac Cardiovasc Surg. 2012;60(12):803–10.

    Article  PubMed  Google Scholar 

  40. Kim DJ, Yang WI, Kim SH, Park IK, Chung KY. Expression of neurotrophin receptors in surgically resected thymic epithelial tumors. Eur J Cardiothorac Surg. 2005;28(4):611–6.

    Article  PubMed  Google Scholar 

  41. Pfister F, Hussain H, Belharazem D, Busch S, Simon-Keller K, Becker D, et al. Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma. Histopathology. 2017;70(5):693–703.

    Article  PubMed  Google Scholar 

  42. Lattanzio R, La Sorda R, Facciolo F, Sioletic S, Lauriola L, Martucci R, et al. Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study. Lung Cancer. 2014;85(2):191–6.

    Article  PubMed  Google Scholar 

  43. Sasaki H, Yukiue H, Kobayashi Y, Nakashima Y, Moriyama S, Kaji M, et al. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg Today. 2001;31(11):1038–40.

    Article  CAS  PubMed  Google Scholar 

  44. Berardi R, Brunelli A, Pagliaretta S, Paolucci V, Conti A, Goteri G, et al. Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy. Oncotarget. 2015;6(22):19305–15.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Wang Y, Thomas A, Lau C, Rajan A, Zhu Y, Killian JK, et al. Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep. 2014;4:7336.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Saito M, Fujiwara Y, Asao T, Honda T, Shimada Y, Kanai Y, et al. The genomic and epigenomic landscape in thymic carcinoma. Carcinogenesis. 2017;38(11):1084–91.

    Article  CAS  PubMed  Google Scholar 

  47. Radovich M, Solzak JP, Hancock BA, Conces ML, Atale R, Porter RF, et al. A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas. Br J Cancer. 2016;114(4):477–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Bellissimo T, Russo E, Ganci F, Vico C, Sacconi A, Longo F, et al. Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors. Cancer Biol Ther. 2016;17(1):79–82.

    Article  CAS  PubMed  Google Scholar 

  49. Bellissimo T, Ganci F, Gallo E, Sacconi A, Tito C, De Angelis L, et al. Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation. Mol Cancer. 2017;16(1):88.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Mokhtar M, Kondo K, Namura T, Ali AH, Fujita Y, Takai C, et al. Methylation and expression profiles of MGMT gene in thymic epithelial tumors. Lung Cancer. 2014;83(2):279–87.

    Article  PubMed  Google Scholar 

  51. Lee HS, Jang HJ, Shah R, Yoon D, Hamaji M, Wald O, et al. Genomic analysis of thymic epithelial tumors identifies novel subtypes associated with distinct clinical features. Clin Cancer Res. 2017;23(16):4855–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, et al. The integrated genomic landscape of thymic epithelial tumors. Cancer Cell. 2018;33(2):244–58.e10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Badve S, Goswami C, Gokmen-Polar Y, Nelson RP, Jr., Henley J, Miller N, et al. Molecular analysis of thymoma. PLoS One 2012;7(8):e42669.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Gokmen-Polar Y, Cook RW, Goswami CP, Wilkinson J, Maetzold D, Stone JF, et al. A gene signature to determine metastatic behavior in thymomas. PLoS One. 2013;8(7):e66047.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Mineo TC, Mineo D, Onorati I, Cufari ME, Ambrogi V. New predictors of response to neoadjuvant chemotherapy and survival for invasive thymoma: a retrospective analysis. Ann Surg Oncol. 2010;17(11):3022–9.

    Article  PubMed  Google Scholar 

  56. Strollo DC, Rosado-de-Christenson ML, Jett JR. Primary mediastinal tumors: part II. Tumors of the middle and posterior mediastinum. Chest. 1997;112(5):1344–57.

    Article  CAS  PubMed  Google Scholar 

  57. Mey U, Hitz F, Lohri A, Pederiva S, Taverna C, Tzankov A, et al. Diagnosis and treatment of diffuse large B-cell lymphoma. Swiss Med Wkly. 2012;142:w13511.

    PubMed  Google Scholar 

  58. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146–71.

    Article  PubMed  Google Scholar 

  59. Weisenburger DD. Environmental epidemiology of non-Hodgkin’s lymphoma in eastern Nebraska. Am J Ind Med. 1990;18(3):303–5.

    Article  CAS  PubMed  Google Scholar 

  60. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008.

    Google Scholar 

  61. De Vita S, Sacco C, Sansonno D, Gloghini A, Dammacco F, Crovatto M, et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood. 1997;90(2):776–82.

    Article  PubMed  Google Scholar 

  62. Luppi M, Longo G, Ferrari MG, Barozzi P, Marasca R, Morselli M, et al. Clinico-pathological characterization of hepatitis C virus-related B-cell non-Hodgkin’s lymphomas without symptomatic cryoglobulinemia. Ann Oncol. 1998;9(5):495–8.

    Article  CAS  PubMed  Google Scholar 

  63. Abrams DI, Kaplan LD, McGrath MS, Volberding PA. AIDS-related benign lymphadenopathy and malignant lymphoma: clinical aspects and virologic interactions. AIDS Res. 1986;2(Suppl 1):S131–40.

    PubMed  Google Scholar 

  64. Gloghini A, Dolcetti R, Carbone A. Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. Semin Cancer Biol. 2013;23(6:457–67.

    Article  CAS  Google Scholar 

  65. Wang F, Xu RH, Han B, Shi YX, Luo HY, Jiang WQ, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer. 2007;109(7):1360–4.

    Article  PubMed  Google Scholar 

  66. Deng L, Song Y, Young KH, Hu S, Ding N, Song W, et al. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. Oncotarget. 2015;6(28):25061–73.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Castillo JJ, Beltran BE, Miranda RN, Paydas S, Winer ES, Butera JN. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist. 2011;16(1):87–96.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y, et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol. 2003;27(1):16–26.

    Article  PubMed  Google Scholar 

  69. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31(11):1860–1.

    CAS  PubMed  Google Scholar 

  70. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: cotswolds meeting. J Clin Oncol. 1989;7(11):1630–6.

    Article  CAS  PubMed  Google Scholar 

  71. Betancourt-Garcia RD, Garcia-Pallas MV, Pacheco E, Castro J, Cabanillas F. Diffuse large-cell lymphoma. Part I: clinical features, histology and prognosis. P R Health Sci J. 2009;28(1):5–11.

    PubMed  Google Scholar 

  72. Caimi PF, Hill BT, Hsi ED, Smith MR. Clinical approach to diffuse large B cell lymphoma. Blood Rev. 2016;30(6):477–91.

    Article  PubMed  Google Scholar 

  73. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61.

    Article  CAS  PubMed  Google Scholar 

  74. Lichtenstein AK, Levine A, Taylor CR, Boswell W, Rossman S, Feinstein DI, et al. Primary mediastinal lymphoma in adults. Am J Med. 1980;68(4):509–14.

    Article  CAS  PubMed  Google Scholar 

  75. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361–92.

    Article  CAS  PubMed  Google Scholar 

  76. Bhatt VR, Mourya R, Shrestha R, Armitage JO. Primary mediastinal large B-cell lymphoma. Cancer Treat Rev. 2015;41(6):476–85.

    Article  PubMed  Google Scholar 

  77. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118(10):2659–69.

    Article  CAS  PubMed  Google Scholar 

  78. Oschlies I, Burkhardt B, Salaverria I, Rosenwald A, d’Amore ES, Szczepanowski M, et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica. 2011;96(2):262–8.

    Article  PubMed  Google Scholar 

  79. Martelli M, Ferreri AJ, Johnson P. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2008;68(3):256–63.

    Article  PubMed  Google Scholar 

  80. Punnett A, Tsang RW, Hodgson DC. Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol. 2010;20(1):30–44.

    Article  PubMed  Google Scholar 

  81. Gobbi PG, Ferreri AJ, Ponzoni M, Levis A. Hodgkin lymphoma. Crit Rev Oncol Hematol. 2013;85(2):216–37.

    Article  PubMed  Google Scholar 

  82. Hjalgrim H, Engels EA. Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence. J Intern Med. 2008;264(6):537–48.

    Article  CAS  PubMed  Google Scholar 

  83. Herbst H, Pallesen G, Weiss LM, Delsol G, Jarrett RF, Steinbrecher E, et al. Hodgkin’s disease and Epstein-Barr virus. Ann Oncol. 1992;3(Suppl 4):27–30.

    Article  PubMed  Google Scholar 

  84. Armstrong AA, Alexander FE, Paes RP, Morad NA, Gallagher A, Krajewski AS, et al. Association of Epstein-Barr virus with pediatric Hodgkin’s disease. Am J Pathol. 1993;142(6):1683–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Brown JR, Neuberg D, Phillips K, Reynolds H, Silverstein J, Clark JC, et al. Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. Br J Haematol. 2008;143(3):361–8.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Townsend W, Linch D. Hodgkin’s lymphoma in adults. Lancet. 2012;380(9844):836–47.

    Article  PubMed  Google Scholar 

  87. Ansell SM. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(4):434–42.

    Article  CAS  PubMed  Google Scholar 

  88. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339(21):1506–14.

    Article  CAS  PubMed  Google Scholar 

  89. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Grant C, Dunleavy K, Eberle FC, Pittaluga S, Wilson WH, Jaffe ES. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep. 2011;6(3):157–63.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Dunleavy K, Grant C, Eberle FC, Pittaluga S, Jaffe ES, Wilson WH. Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma? Curr Hematol Malig Rep. 2012;7(3):241–7.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Wilson WH, Pittaluga S, Nicolae A, Camphausen K, Shovlin M, Steinberg SM, et al. A prospective study of mediastinal gray-zone lymphoma. Blood. 2014;124(10):1563–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Sarkozy C, Molina T, Ghesquieres H, Michallet AS, Dupuis J, Damotte D, et al. Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. Haematologica. 2017;102(1):150–9.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Quintanilla-Martinez L, Fend F. Mediastinal gray zone lymphoma. Haematologica. 2011;96:496–9.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Cazals-Hatem D, Andre M, Mounier N, Copin MC, Divine M, Berger F, et al. Pathologic and clinical features of 77 Hodgkin’s lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study. Am J Surg Pathol. 2001;25(3):297–306.

    Article  CAS  PubMed  Google Scholar 

  96. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.

    Article  CAS  PubMed  Google Scholar 

  97. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Testoni M, Zucca E, Young KH, Bertoni F. Genetic lesions in diffuse large B-cell lymphomas. Ann Oncol. 2015;26(6):1069–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Lo Coco F, Ye BH, Lista F, Corradini P, Offit K, Knowles DM, et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin’s lymphoma. Blood. 1994;83(7):1757–9.

    Article  CAS  PubMed  Google Scholar 

  100. Ye BH, Chaganti S, Chang CC, Niu H, Corradini P, Chaganti RS, et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J. 1995;14(24):6209–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004;432(7017):635–9.

    Article  CAS  PubMed  Google Scholar 

  102. Basso K, Schneider C, Shen Q, Holmes AB, Setty M, Leslie C, et al. BCL6 positively regulates AID and germinal center gene expression via repression of miR-155. J Exp Med. 2012;209(13):2455–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Shustik J, Han G, Farinha P, Johnson NA, Ben Neriah S, Connors JM, et al. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica. 2010;95(1):96–101.

    Article  CAS  PubMed  Google Scholar 

  104. Akyurek N, Uner A, Benekli M, Barista I. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 2012;118(17):4173–83.

    Article  CAS  PubMed  Google Scholar 

  105. Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais JP, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol. 2009;27(33):5573–9.

    Article  PubMed  Google Scholar 

  106. Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004;165(1):159–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Saito M, Novak U, Piovan E, Basso K, Sumazin P, Schneider C, et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2009;106(27):11294–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Schuetz JM, Johnson NA, Morin RD, Scott DW, Tan K, Ben-Nierah S, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia. 2012;26(6):1383–90.

    Article  CAS  PubMed  Google Scholar 

  109. Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res. 2011;17(24):7785–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013;98(2):255–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Kusumoto S, Kobayashi Y, Sekiguchi N, Tanimoto K, Onishi Y, Yokota Y, et al. Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a “non-germinal center phenotype”. Am J Surg Pathol. 2005;29(8):1067–73.

    Article  PubMed  Google Scholar 

  112. Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(6):961–8.

    Article  CAS  PubMed  Google Scholar 

  113. Nowakowski GS, Czuczman MS. ABC, GCB, and double-hit diffuse large B-cell lymphoma: does subtype make a difference in therapy selection? Am Soc Clin Oncol Educ Book. 2015:e449–57.

    Article  Google Scholar 

  114. Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205–17.

    Article  CAS  PubMed  Google Scholar 

  115. Perry AM, Mitrovic Z, Chan WC. Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control. 2012;19(3):214–26.

    Article  PubMed  Google Scholar 

  116. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2011;117(8):2451–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Wigle TJ, Knutson SK, Jin L, Kuntz KW, Pollock RM, Richon VM, et al. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett. 2011;585(19):3011–4.

    Article  CAS  PubMed  Google Scholar 

  118. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012;109(52):21360–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Garapaty-Rao S, Nasveschuk C, Gagnon A, Chan EY, Sandy P, Busby J, et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol. 2013;20(11):1329–39.

    Article  CAS  PubMed  Google Scholar 

  120. Song X, Zhang L, Gao T, Ye T, Zhu Y, Lei Q, et al. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation. Biomed Pharmacother. 2016;81:288–94.

    Article  CAS  PubMed  Google Scholar 

  121. Honma D, Kanno O, Watanabe J, Kinoshita J, Hirasawa M, Nosaka E, et al. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. Cancer Sci. 2017;108(10):2069–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471(7337):189–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Chigrinova E, Mian M, Shen Y, Greiner TC, Chan WC, Vose JM, et al. Integrated profiling of diffuse large B-cell lymphoma with 7q gain. Br J Haematol. 2011;153(4):499–503.

    Article  PubMed  Google Scholar 

  124. Jardin F, Jais JP, Molina TJ, Parmentier F, Picquenot JM, Ruminy P, et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood. 2010;116(7):1092–104.

    Article  CAS  PubMed  Google Scholar 

  125. Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012;22(3):359–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471(7338):377–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An J, Jones SJ, et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121(18):3666–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Dominguez-Sola D, Kung J, Holmes AB, Wells VA, Mo T, Basso K, et al. The FOXO1 transcription factor instructs the germinal center dark zone program. Immunity. 2015;43(6):1064–74.

    Article  CAS  PubMed  Google Scholar 

  129. Weniger MA, Barth TF, Moller P. Genomic alterations in Hodgkin’s lymphoma. Int J Hematol. 2006;83(5):379–84.

    Article  CAS  PubMed  Google Scholar 

  130. Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Ho A, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med. 1999;189(12):1939–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99(2):618–26.

    Article  CAS  PubMed  Google Scholar 

  132. Falzetti D, Crescenzi B, Matteuci C, Falini B, Martelli MF, Van Den Berghe H, et al. Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin’s disease. Haematologica. 1999;84(4):298–305.

    CAS  PubMed  Google Scholar 

  133. Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegelberger B, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood. 2002;99(4):1474–7.

    Article  CAS  PubMed  Google Scholar 

  134. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin’s disease suggest a tumour suppressor role for IkappaBalpha. Oncogene. 1999;18(20):3063–70.

    Article  CAS  PubMed  Google Scholar 

  135. Emmerich F, Theurich S, Hummel M, Haeffker A, Vry MS, Dohner K, et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol. 2003;201(3):413–20.

    Article  CAS  PubMed  Google Scholar 

  136. Trumper LH, Brady G, Bagg A, Gray D, Loke SL, Griesser H, et al. Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood. 1993;81(11):3097–115.

    Article  CAS  PubMed  Google Scholar 

  137. Muschen M, Re D, Brauninger A, Wolf J, Hansmann ML, Diehl V, et al. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res. 2000;60(20):5640–3.

    CAS  PubMed  Google Scholar 

  138. Seitz V, Hummel M, Anagnostopoulos I, Stein H. Analysis of BCL-6 mutations in classic Hodgkin disease of the B- and T-cell type. Blood. 2001;97(8):2401–5.

    Article  CAS  PubMed  Google Scholar 

  139. Joos S, Granzow M, Holtgreve-Grez H, Siebert R, Harder L, Martin-Subero JI, et al. Hodgkin’s lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer. 2003;103(4):489–95.

    Article  CAS  PubMed  Google Scholar 

  140. Barth TF, Martin-Subero JI, Joos S, Menz CK, Hasel C, Mechtersheimer G, et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003;101(9):3681–6.

    Article  CAS  PubMed  Google Scholar 

  141. Joos S, Menz CK, Wrobel G, Siebert R, Gesk S, Ohl S, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002;99(4):1381–7.

    Article  CAS  PubMed  Google Scholar 

  142. Re D, Benenson E, Wolf J, Diehl V, Staratschek-Jox A. Lack of BCL10 mutations in Hodgkin’s disease-derived cell lines. Br J Haematol. 2000;109(2):420–2.

    Article  CAS  PubMed  Google Scholar 

  143. Cochet O, Frelin C, Peyron JF, Imbert V. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal. 2006;18(4):449–55.

    Article  CAS  PubMed  Google Scholar 

  144. Weniger MA, Melzner I, Menz CK, Wegener S, Bucur AJ, Dorsch K, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25(18):2679–84.

    Article  CAS  PubMed  Google Scholar 

  145. Kupper M, Joos S, von Bonin F, Daus H, Pfreundschuh M, Lichter P, et al. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol. 2001;112(3):768–75.

    Article  CAS  PubMed  Google Scholar 

  146. Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111(6):3220–4.

    Article  CAS  PubMed  Google Scholar 

  147. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O’Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. Garcia MJ, Martinez-Delgado B, Cebrian A, Martinez A, Benitez J, Rivas C. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin’s and CD30-Positive non-Hodgkin’s lymphomas. Am J Pathol. 2002;161(3):1007–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Sanchez-Aguilera A, Delgado J, Camacho FI, Sanchez-Beato M, Sanchez L, Montalban C, et al. Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood. 2004;103(6):2351–7.

    Article  CAS  PubMed  Google Scholar 

  150. Murray PG, Qiu GH, Fu L, Waites ER, Srivastava G, Heys D, et al. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin’s lymphoma. Oncogene. 2004;23(6):1326–31.

    Article  CAS  PubMed  Google Scholar 

  151. Dukers DF, van Galen JC, Giroth C, Jansen P, Sewalt RG, Otte AP, et al. Unique polycomb gene expression pattern in Hodgkin’s lymphoma and Hodgkin’s lymphoma-derived cell lines. Am J Pathol. 2004;164(3):873–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207(2):243–9.

    Article  CAS  PubMed  Google Scholar 

  153. Rossi D, Cerri M, Capello D, Deambrogi C, Berra E, Franceschetti S, et al. Aberrant somatic hypermutation in primary mediastinal large B-cell lymphoma. Leukemia. 2005;19:2363–6.

    Article  CAS  PubMed  Google Scholar 

  154. Scarpa A, Moore PS, Rigaud G, Inghirami G, Montresor M, Menegazzi M, et al. Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc. Br J Haematol. 1999;107(1):106–13.

    Article  CAS  PubMed  Google Scholar 

  155. Tsang P, Cesarman E, Chadburn A, Liu YF, Knowles DM. Molecular characterization of primary mediastinal B cell lymphoma. Am J Pathol. 1996;148(6):2017–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  156. Capello D, Vitolo U, Pasqualucci L, Quattrone S, Migliaretti G, Fassone L, et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood. 2000;95(2):651–9.

    CAS  PubMed  Google Scholar 

  157. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871–9.

    Article  CAS  PubMed  Google Scholar 

  158. Weniger MA, Gesk S, Ehrlich S, Martin-Subero JI, Dyer MJ, Siebert R, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer. 2007;46(4):406–15.

    Article  CAS  PubMed  Google Scholar 

  159. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106(9):3183–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  160. Wessendorf S, Barth TF, Viardot A, Mueller A, Kestler HA, Kohlhammer H, et al. Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia. 2007;21(12):2463–9.

    Article  CAS  PubMed  Google Scholar 

  161. Takahashi H, Feuerhake F, Monti S, Kutok JL, Aster JC, Shipp MA. Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma. Blood. 2006;107:844–5.

    Article  CAS  PubMed  Google Scholar 

  162. Joos S, Otano-Joos MI, Ziegler S, Bruderlein S, du Manoir S, Bentz M, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood. 1996;87(4):1571–8.

    Article  CAS  PubMed  Google Scholar 

  163. Joos S, Kupper M, Ohl S, von Bonin F, Mechtersheimer G, Bentz M, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 2000;60(3):549–52.

    CAS  PubMed  Google Scholar 

  164. Roberts RA, Wright G, Rosenwald AR, Jaramillo MA, Grogan TM, Miller TP, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood. 2006;108(1):311–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Eberle FC, Salaverria I, Steidl C, Summers TA Jr, Pittaluga S, Neriah SB, et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol. 2011;24(12):1586–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  166. Eberle FC, Rodriguez-Canales J, Wei L, Hanson JC, Killian JK, Sun HW, et al. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma. Haematologica. 2011;96(4):558–66.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy

    Francesca Pentimalli & Daniela Barone

  2. Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA

    Antonio Giordano

  3. Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy

    Antonio Giordano

Authors
  1. Francesca Pentimalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela Barone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio Giordano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesca Pentimalli .

Editor information

Editors and Affiliations

  1. Pathology Unit, Department of Mental and Physic Health and Preventive Medicine, Università della Campania ‘Luigi Vanvitelli’, Naples, Italy

    Renato Franco

  2. Pathology Unit, Department of Mental and Physic Health and Preventive Medicine, Università della Campania ‘Luigi Vanvitelli’, Naples, Italy

    Federica Zito Marino

  3. Sbarro Institute for Cancer Research, Temple University Sbarro Institute for Cancer Research, Philadelphia, PA, USA

    Antonio Giordano

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pentimalli, F., Barone, D., Giordano, A. (2018). Thymic Tumors and Lymphomas: The Clinical Impact of Their Underlying Molecular Features. In: Franco, R., Zito Marino, F., Giordano, A. (eds) The Mediastinal Mass. Current Clinical Pathology. Humana, Cham. https://doi.org/10.1007/978-3-319-90368-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90368-2_7

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-319-90367-5

  • Online ISBN: 978-3-319-90368-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation